American Century Companies’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-78,949
| Closed | -$787K | – | 2836 |
|
|
2025
Q2 | $787K | Buy |
78,949
+4,417
| +6% | +$35.6K | ﹤0.01% | 2373 |
|
|
2025
Q1 | $445K | Buy |
74,532
+6,595
| +10% | +$48.4K | ﹤0.01% | 2554 |
|
|
2024
Q4 | $522K | Buy |
67,937
+4,727
| +7% | +$40.6K | ﹤0.01% | 2492 |
|
|
2024
Q3 | $645K | Buy |
63,210
+16,888
| +36% | +$258K | ﹤0.01% | 2387 |
|
|
2024
Q2 | $687K | Buy |
46,322
+9,717
| +27% | +$139K | ﹤0.01% | 2323 |
|
|
2024
Q1 | $499K | Buy |
36,605
+9,801
| +37% | +$107K | ﹤0.01% | 2454 |
|
|
2023
Q4 | $294K | Sell |
26,804
-24,751
| -48% | -$245K | ﹤0.01% | 2575 |
|
|
2023
Q3 | $565K | Sell |
51,555
-19,491
| -27% | -$249K | ﹤0.01% | 2223 |
|
|
2023
Q2 | $941K | Sell |
71,046
-39,244
| -36% | -$560K | ﹤0.01% | 1973 |
|
|
2023
Q1 | $1.45M | Sell |
110,290
-62,416
| -36% | -$1.12M | ﹤0.01% | 1726 |
|
|
2022
Q4 | $3.37M | Sell |
172,706
-49,766
| -22% | -$972K | ﹤0.01% | 1374 |
|
|
2022
Q3 | $4.24M | Buy |
222,472
+57,252
| +35% | +$1.32M | ﹤0.01% | 1174 |
|
|
2022
Q2 | $3.4M | Buy |
165,220
+43,825
| +36% | +$1.04M | ﹤0.01% | 1252 |
|
|
2022
Q1 | $3.91M | Buy |
121,395
+73,187
| +152% | +$2.66M | ﹤0.01% | 1181 |
|
|
2021
Q4 | $2.25M | Buy |
+48,208
| New | +$1.6M | ﹤0.01% | 1318 |
|
Other funds holding ITOS
American Century Companies's ITOS Position: Q3 2025 in Review
American Century Companies sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 78,949 shares — an estimated $787K sold.
American Century Companies first reported a position in ITOS in Q4 2021 and held it in 15 quarters. The position peaked at $4.24M in Q3 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- American Century Companies reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- American Century Companies sold 78,949 iTeos Therapeutics shares in Q3 2025, an estimated $787K.
- American Century Companies first reported a position in iTeos Therapeutics in Q4 2021 and held it in 15 quarters.
- American Century Companies's iTeos Therapeutics position peaked at $4.24M in Q3 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on American Century Companies's 13F filing for Q3 2025, filed 12 Nov 2025.